These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

402 related items for PubMed ID: 23007746

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO, Ehlermann P, Koch A, Remppis A, Katus HA, Dengler TJ.
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. How delayed graft function impacts exposure to mycophenolic acid in patients after renal transplantation.
    van Gelder T, Silva HT, de Fijter H, Budde K, Kuypers D, Mamelok RD, Armstrong VW, Oellerich M.
    Ther Drug Monit; 2011 Apr; 33(2):155-64. PubMed ID: 21383657
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure.
    Tett SE, Saint-Marcoux F, Staatz CE, Brunet M, Vinks AA, Miura M, Marquet P, Kuypers DR, van Gelder T, Cattaneo D.
    Transplant Rev (Orlando); 2011 Apr; 25(2):47-57. PubMed ID: 21190834
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes.
    Budde K, Glander P, Krämer BK, Fischer W, Hoffmann U, Bauer S, Grohmann J, Neumayer HH, Arns W.
    Transplantation; 2007 Feb 27; 83(4):417-24. PubMed ID: 17318074
    [Abstract] [Full Text] [Related]

  • 12. The pharmacokinetics of mycophenolate mofetil in Thai kidney transplant recipients.
    Jirasiritham S, Sumethkul V, Mavichak V, Na-Bangchang K.
    Transplant Proc; 2004 Sep 27; 36(7):2076-8. PubMed ID: 15518751
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation.
    Mourad M, Malaise J, Chaib Eddour D, De Meyer M, König J, Schepers R, Squifflet JP, Wallemacq P.
    Clin Chem; 2001 Sep 27; 47(7):1241-8. PubMed ID: 11427455
    [Abstract] [Full Text] [Related]

  • 14. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial.
    van Gelder T, Silva HT, de Fijter JW, Budde K, Kuypers D, Tyden G, Lohmus A, Sommerer C, Hartmann A, Le Meur Y, Oellerich M, Holt DW, Tönshoff B, Keown P, Campbell S, Mamelok RD.
    Transplantation; 2008 Oct 27; 86(8):1043-51. PubMed ID: 18946341
    [Abstract] [Full Text] [Related]

  • 15. Mycophenolic acid pharmacokinetics in pediatric liver transplant recipients.
    Aw MM, Brown NW, Itsuka T, Gonde CE, Adams JE, Heaton ND, Tredger JM, Mieli-Vergani G, Dhawan A.
    Liver Transpl; 2003 Apr 27; 9(4):383-8. PubMed ID: 12682891
    [Abstract] [Full Text] [Related]

  • 16. Age-related variability of mycophenolate mofetil exposure in stable pediatric liver transplant recipients and influences of donor characteristics.
    Parant F, Rivet C, Boulieu R, Gagnieu MC, Dumortier J, Boillot O, Lachaux A.
    Ther Drug Monit; 2009 Dec 27; 31(6):727-33. PubMed ID: 19881404
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Mycophenolate sodium dosing in combination with tacrolimus: pharmacokinetic evaluation of a novel regimen in de novo tacrolimus-treated kidney transplant patients.
    Pons B, Delavenne X, Mehdi M, Maillard N, Sauron C, Berthoux F, Alamartine E, Basset T, Mariat C.
    Clin Nephrol; 2012 Jun 27; 77(6):425-31. PubMed ID: 22595383
    [Abstract] [Full Text] [Related]

  • 19. Long-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration: a prospective study in 100 de novo renal allograft recipients.
    Kuypers DR, Claes K, Evenepoel P, Maes B, Coosemans W, Pirenne J, Vanrenterghem Y.
    J Clin Pharmacol; 2003 Aug 27; 43(8):866-80. PubMed ID: 12953344
    [Abstract] [Full Text] [Related]

  • 20. Lower dosing of enteric-coated mycophenolate sodium (Myfortic) can achieve target mycophenolic acid exposure rapidly in most Chinese renal transplant patients: a pilot study.
    Yin H, Qiu K, Hu XP, Li XB, Wang W, Liu LH, Zhang XD.
    Int J Clin Pract Suppl; 2014 Apr 27; (181):31-7. PubMed ID: 24673717
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.